Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Developing a clinical pathway for breathlessness in primary care based on analysis of routine primary care data

    General practice and primary care Date published:

  • Development of patient resources for chronic breathlessness: Needs analysis

    General practice and primary care Date published:

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Protocol for a randomized controlled trial of medically tailored meals compared to usual care among individuals with type 2 diabetes in Australia

    Contemporary Clinical Trials Date published:

  • Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

    Journal of the American College of Cardiology Date published:

  • Artificial Intelligence in Cardiology: An Australian Perspective

    Heart, Lung and Circulation Date published:

  • Risks and Burdens of Unplanned Heart Failure Readmissions: How to Cut a Gordian Knot?

    Heart, Lung and Circulation Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases Date published:

  • “It's like a forgotten issue sometimes …”: Qualitative study of individuals living and caring for people with chronic breathlessness

    The Clinical Respiratory Journal Date published:

  • Sex-Specific Clinical and Genetic Factors Associated with Adverse Outcomes in Hypertrophic Cardiomyopathy

    Unknown Date published:

  • Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

    BMJ Open Diabetes Research & Care Date published:

  • Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER

    European Heart Journal Date published:

  • Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published: